SANA
Sana Biotechnology IncNASDAQ
Healthcare • Biotechnology
Factor tilt: Small-Cap Blend
$2.37+1.28%
Close Nov 6, 2026
- Market cap
- $659.55M
- 1 month
- -15.1%
- 3 months
- -34.3%
- 1 year
- -41.9%
- 52-week range
- $2.27$5.18
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.13Quarter to Sep 30, 2026 · 4 analysts · 0.0% in 30d
- Short interest
- 21.4% of float40.8M shares · settled Oct 15, 2026 · +5.5% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$211.82M
- Free cash flow
- -$135.06M
- Book value
- $154.57M
- Total debt
- $73.74M
- P/E
- —
- Price / sales
- —
- Price / book
- 4.3×
- FCF yield
- -20.5%
- Net margin
- —
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology.
Read more
The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
- Website
- sana.com
- Headquarters
- Seattle, WA, United States
- Employees
- 142
- Listed
- Feb 4, 2021
- Fiscal year ends
- December
Company profile from EODHD, stored Oct 23, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 10, 2026 | — | — | — | -$65.4M | -$63.6M |
| Mar 2026filed May 11, 2026 | — | — | — | -$37.9M | -$47.2M |
| Dec 2025filed Mar 3, 2026 | — | — | — | -$61.2M | -$58.8M |
| Sep 2025filed Nov 6, 2025 | — | — | — | -$43.5M | -$42.2M |
| Jun 2025filed Aug 11, 2025 | — | — | — | -$95.0M | -$93.8M |
| Mar 2025filed May 8, 2025 | — | — | — | -$50.6M | -$49.4M |
| Dec 2024filed Mar 17, 2025 | $15.3M | — | 50.0% | -$50.9M | -$49.1M |
| Sep 2024filed Nov 8, 2024 | — | — | — | -$61.8M | -$59.9M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 3, 2026 | — | — | — | -$191.0M | -$244.2M |
| Dec 2024filed Mar 17, 2025 | — | — | — | -$272.7M | -$266.8M |
| Dec 2023filed Dec 31, 2023 | — | — | — | -$293.1M | -$283.3M |
| Dec 2022filed Mar 16, 2023 | — | — | — | -$272.6M | -$266.4M |
| Dec 2021filed Mar 16, 2022 | — | — | — | -$356.9M | -$344.2M |
| Dec 2020filed Mar 24, 2021 | — | — | — | -$286.1M | -$278.6M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched SANA. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
40,846,893 shares short
+2,121,194 shares (+5.5%) vs Sep 30, 2026
21.4% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
38,725,699 shares short
-2,649,112 shares (-6.4%) vs Sep 15, 2026
20.3% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
41,374,811 shares short
-188,523 shares (-0.5%) vs Aug 31, 2026
21.9% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
41,563,334 shares short
-1,005,641 shares (-2.4%) vs Aug 14, 2026
22% of the stored float. Published Sep 10, 2026.
Settlement Aug 14, 2026
42,568,975 shares short
+420,968 shares (+1%) vs Jul 31, 2026
22.6% of the stored float. Published Aug 25, 2026.
Settlement Jul 31, 2026
42,148,007 shares short
+2,411,627 shares (+6.1%) vs Jul 15, 2026
22.3% of the stored float. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind SANA’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
No qualified split events are stored. This does not establish that the stock has never split.
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if SANA is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
26 smart-money holders: institutions with a high Holder IQ
Q2 2026, filed Oct 27, 2026
Smart-money 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 1
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Largest 13-F holders · Q2 2026
211 filers reported a long position in SANA for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
The top 10 hold
76.9%
of the 184.8M shares 13-F filers reported
Moves vs Q1 2026
5 added3 trimmed
1 new · 1 unchanged
Net shares held
+6.3%
across the 9 holders with a comparable Q1 2026 book
| Rank | Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|---|
| 1 | FMR LLC | $130.6M · 37.4M shares | 37.4M | 0% |
| 2 | Flagship Pioneering, LLC | $87.3M · 25M shares | 25M | Unchanged |
| 3 | RA CAPITAL MANAGEMENT, L.P. | $65.4M · 18.8M shares | 18.8M | New |
| 4 | BlackRock, Inc. | $58.2M · 16.7M shares | 16.7M | +17.1% |
| 5 | STATE STREET CORP | $39.1M · 11.2M shares | 11.2M | +6.3% |
| 6 | CANADA PENSION PLAN INVESTMENT BOARD | $35.7M · 10.2M shares | 10.2M | 0% |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | $29.2M · 8.4M shares | 8.4M | +12.7% |
| 8 | BANK OF AMERICA CORP /DE/ | $20.1M · 5.7M shares | 5.7M | +95.1% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | $16.3M · 4.7M shares | 4.7M | +11.9% |
| 10 | Marex Group Ltd | $13.9M · 4M shares | 4M | -0.3% |
Sign in to see each holder’s Holder IQ, factor-adjusted Holder IQ and rank, and compare these holders with all scored filers. Available on every plan.
Sign in5% holder filings (13D / 13G)
Holders of more than 5% of SANA file with the SEC within days. A 13D holder may seek to influence the company; a 13G holder is passive. Each holder’s latest filing from the last three years.
| Filed | Holder | % of class |
|---|---|---|
| Nov 5, 2026 | FMR LLC13G · passive · amended | 12.5% |
| Aug 14, 2026 | ARCH Venture Fund IX LP13G · passive · amended | 15.4% |
| May 21, 2026 | RA CAPITAL MANAGEMENT, L.P.13G · passive | 6.3% |
Get the Full Analysis for SANA
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.